<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062101</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02720</org_study_id>
    <secondary_id>LUNG 2002-01</secondary_id>
    <secondary_id>NCI-5416</secondary_id>
    <secondary_id>CDR0000304495</secondary_id>
    <nct_id>NCT00062101</nct_id>
  </id_info>
  <brief_title>Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving erlotinib together with celecoxib works in&#xD;
      treating patients with recurrent stage IIIB or stage IV non-small cell lung cancer. Erlotinib&#xD;
      and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor&#xD;
      cell growth. Celecoxib may slow the growth of a tumor by stopping blood flow to the tumor.&#xD;
      Combining erlotinib with celecoxib may kill more tumor cells.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate of patients with stage IIIB or IV recurrent non-small cell&#xD;
      lung cancer treated with erlotinib and celecoxib as second-line therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the time to progression in patients treated with this regimen. II. Determine the&#xD;
      survival duration of patients treated with this regimen. III. Determine the toxicity of this&#xD;
      regimen in these patients. IV. Correlate the expression of epidermal growth factor receptor&#xD;
      and cyclooxygenase-2 in tumor specimens with response, time to progression, and survival in&#xD;
      patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
      Group 1: Patients receive oral erlotinib once daily and oral celecoxib twice daily.&#xD;
&#xD;
      Group 2: Patients receive erlotinib as in group 1.&#xD;
&#xD;
      Treatment in both groups continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40-80 patients will be accrued for this study within 10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>From the start of treatment until disease progression/recurrence, assessed up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Interval between start of treatment with erlotinib hydrochloride and celecoxib and the date on which progressive disease, assessed up to 5 years</time_frame>
    <description>Will be analyzed by calculating Kaplan Meier curves and estimating medians and 95% confidence intervals using the method of Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be analyzed by calculating Kaplan Meier curves and estimating medians and 95% confidence intervals using the method of Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between measures of treatment efficacy and EGFR and COX-2 levels</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI Common Toxicity Criteria (CTC) version 2.0</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group I (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib once daily and oral celecoxib twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib as in group 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally (PO)</description>
    <arm_group_label>Group I (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <arm_group_label>Group II (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>SC-58635</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <arm_group_label>Group II (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIB (malignant pleural effusion only) or IV&#xD;
&#xD;
          -  Recurrent disease that has progressed after 1 or 2 prior chemotherapy regimens&#xD;
             (platinum- or nonplatinum-based)&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion*&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  Must have tissue specimen available for assays&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper normal limit (ULN)&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No prior abnormalities of the cornea (e.g., dry eye syndrome or Sj√∂gren's syndrome)&#xD;
&#xD;
          -  No congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
          -  No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)&#xD;
&#xD;
          -  No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production&#xD;
             test)&#xD;
&#xD;
          -  Able to ingest oral medication&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
          -  No active gastrointestinal ulcers&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No significant traumatic injury within the past 21 days&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No prior allergic reactions to sulfonamides, aspirin, and other nonsteroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
          -  No prior monoclonal antibodies to epidermal growth factor receptor (EGFR)&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  More than 21 days since prior major surgery&#xD;
&#xD;
          -  No prior surgery affecting absorption&#xD;
&#xD;
          -  No prior EGFR-specific tyrosine kinases&#xD;
&#xD;
          -  No concurrent anticonvulsants&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent antacids&#xD;
&#xD;
          -  No concurrent administration of any of the following drugs:&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Chloramphenicol&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Omeprazole&#xD;
&#xD;
               -  Zafirlukast&#xD;
&#xD;
               -  Clopidogrel&#xD;
&#xD;
               -  Cotrimoxazole&#xD;
&#xD;
               -  Disulfiram&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Fluoxetine&#xD;
&#xD;
               -  Fluvastatin&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Isoniazid&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Leflunomide&#xD;
&#xD;
               -  Metronidazole&#xD;
&#xD;
               -  Modafinil&#xD;
&#xD;
               -  Paroxetine&#xD;
&#xD;
               -  Phenylbutazone&#xD;
&#xD;
               -  Sertraline&#xD;
&#xD;
               -  Ticlopidine&#xD;
&#xD;
               -  Valproic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Bonomi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

